Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 12, 2012

View Archived Issues

Ono Pharmaceutical updates progress of second quarter of fiscal 2012

Pevion Biotech launches new immune enhancement platform

Successful results reported for phase IIb trial of bremelanotide

XenoPort reacquires rights to Horizant

SGX-203 granted FDA fast track designation

Novel RNAi therapeutic significantly reduces triglycerides and LDL

Mutations in CYP26C1 associated with FFDD type IV

Kowa describes preclinical testing of novel cholesteryl ester transfer protein inhibitor

Researchers at Compugen present new fusion proteins

VS-5584 treatment inhibits cancer stem cells in vitro and in vivo

U.S. team prepares novel MAbs for cancer

New antibacterial agents synthesized by Canadian researchers

Novel BACE1/BACE2 inhibitors divulged by Merck & Co.

Scientists at Merck & Co. report novel MR antagonists

Biotron begins phase II BIT-225 trial in patients with HIV and HCV

Biota provides update on merger

Daiichi Sankyo submits supplemental NDA for Topotecin in Japan

FDA advisory committee votes on insulin degludec NDAs

Novel biomarker for the diagnosis of ACS presented by Japanese group

Myrexis board approves plan of complete liquidation and dissolution

Promising phase I results reported for subcutaneous MOR-103

AstraZeneca reports topline results from pivotal trials of naloxegol

Researchers in Australia present new agents for glaucoma

Pharma Eight presents novel agents for Alzheimer's disease

Pivotal HEAT Study of ThermoDox in primary liver cancer reaches target for unblinding

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...